A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
AssigneeAnavex Life Sciences Corp.
InventorsChristopher U. Missling, Cameron Durrant
Life of this patent
Estimating the term…
Abstract
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
Claims20
A dosage form comprising a therapeutically effective amount of an active,
- wherein the active is
- (i) tetrahydro-N-methyl-2,2-diphenyl-3-furanomethanamine, or a pharmaceutically acceptable salt thereof;
- (ii) tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanomethanamine, or a pharmaceutically acceptable salt thereof;
- or
- a combination of (i) and (ii);
- and
- wherein the therapeutically effective amount is the amount to elicit pharmacological response of reduction in the daily number of seizures by at least 50%.
A method of prophylaxis of seizures in a subject in need of such treatment comprising administering to the subject a low dose donepezil in conjunction with a therapeutic effective amount of tetrahydro-N-methyl-2,2-diphenyl-3-furanomethanamine, or a pharmaceutically acceptable salt thereof;
- wherein the method elicits reduction in the daily number of seizures by at least 50%;
- and
- wherein the therapeutic effective amount is 0.5-10 mg/day.
Dependencies are inferred from the claim text.